Immunoassay Market 1 14

Pharmaceutical Contract Development And Manufacturing Market Revenue to Cross $ 174.2 Bn by 2027


New York: The Report on Pharmaceutical Contract Development And Manufacturing Market by Decisive Markets Insights was released in the middle of Covid -19 after a thorough analysis of the top players and primary interviews with key industry figures. A market study from Pharmaceutical Contract Development And Manufacturing Market examines the market size, segmentation, future trends, growth rate, drivers and challenges, as well as the sales channels and distributors. The global Pharmaceutical Contract Development And Manufacturing market gathered revenue around USD 119.7 Billion in 2020 and market is set to grow USD 174.2 Billion by the end of 2027 and is estimated to expand at a modest CAGR of 8.2% during the prediction period 2021 to 2027.

Overview of Pharmaceutical Contract Development And Manufacturing Market Study

Pharmaceutical Contract Development And Manufacturing market study conducted by Nova One Advisor is intended at helping stakeholders get a comprehensive overview of potential challenges and undiscovered opportunities. The report offers exclusive insights to help companies and their customers to make informed decision to sustain growth through the assessment period.

Get your Customized Research Report@

Growth Factors:

Market growth is driven mainly by factors such as rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs. The increasing demand for biological therapies, growing focus on specialty medicines, growth in the nuclear medicines sector, and advancements in cell and gene therapies are also expected to offer market growth opportunities in the coming years.

Global the pharmaceutical contract development and manufacturing market Dynamics
DRIVER: Patent expiry and increasing demand for generic drugs
Generics are cost-effective drugs with therapeutic effectiveness and safety profiles that are similar to their branded counterparts. The increasing pressure on reducing the rising healthcare costs is one of the major factors driving the growth of the generics market. Considering such cost benefits, governments across various countries are promoting the use of generic drugs.

The patent expiry of several drugs is another major factor driving the growth of the generics market. In developing countries such as South Korea, around 62 patents for 158 pharmaceutical products are scheduled to expire in 2021. Although generic erosion because of the patent cliff has resulted in significant revenue and volume losses for the branded drugs industry, patent expiration enables the entry of several cheaper generic counterparts in the market (which will boost the volume of drugs sold). This is a positive indicator of market growth, as generics companies outsource around 80% of their production to CDMOs.

OPPORTUNITY: Growing demand for cell and gene therapies
Given the personalized nature of cell and gene therapies, they are highly specific and hold the potential to address unmet medical needs associated with treating several disorders. Their promising therapeutic potential has led many pharmaceutical companies and investors to put in a significant amount of capital towards developing and commercializing these therapies. As of February 2020, nine cell and gene therapies are approved by the US FDA. In 2020, around 362 cell and gene therapies were under clinical development. The growing number of cell therapy candidates, coupled with their rapid progression through the various phases of clinical development and their complex manufacturing process, increases the demand for facilities that offer manufacturing services for these therapies.

Buy Complete Assessment of Pharmaceutical Contract Development And Manufacturing market Now@

COVID-19 Impact on Pharmaceutical Contract Development And Manufacturing Sales

Businesses today are operating in a dynamic environment. Earlier focus primarily concentrated on keeping pace with changing consumer preferences. COVID-19 outbreak was unprecedented and exposed vulnerabilities of various industries. Pandemic-induces obstacles also were registered in the Pharmaceutical Contract Development And Manufacturing market.

Sales plummeted as COVID-19 gradually tightened its noose worldwide. Supply-chain disruptions caused massive losses, while demand took nose-dive as consumers remained indoors with affected countries implementing either partial or complete lockdown.

Gradual recovery however is on the cards with the roll out of vaccinations. Nonetheless, consecutive waves of the virus compelled businesses to stay prepared for the worst. As government and healthcare organizations successfully implement steps to contain the spread of COVID-19, industries have begun operations, albeit at a slow and more cautious pace.

Against this backdrop, Nova one advisor’s study predicts gradual recovery for the Pharmaceutical Contract Development And Manufacturing market 2021 onwards. This trend will however continue through the course of the report’s assessment period

Key Players:

This report provides detailed company profiles of the key market players. This research report also highlights the competitive landscape of the Pharmaceutical Contract Development And Manufacturing market and ranks noticeable companies as per their occurrence in diverse regions across globe and crucial developments initiated by them in the market space. This research study also tracks and evaluates competitive developments, such as collaborations, partnerships, and agreements, mergers and acquisitions; novel product introductions and developments, promotion strategies and Research and Development (R&D) activities in the marketplace. The competitive profiling of these players includes business and financial overview, gross margin, production, sales, and recent developments which can aid in assessing competition in the market.

Some of the prominent players in the Pharmaceutical Contract Development And Manufacturing market include:

 Catalent; Pharmaceutical Product Development LLC; AbbVie; Baxter BioPharma Solutions; Patheon; Grifols International, S.A.; Dalton Pharma Services; Boehringer Ingelheim Biopharmaceuticals GmbH; Lonza AG

Unravelling the Critical Segments

This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects including product type, application/end-user, and region. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for period 2017 to 2027 and covers subsequent region in its scope:

Pharmaceutical Contract Development and Manufacturing Market, by Service

  • Pharmaceutical Manufacturing Services
    • Pharmaceutical API Manufacturing Services
    • Pharmaceutical FDF Manufacturing Services
      • Parenteral/injectable manufacturing services
      • Tablet manufacturing services
      • Capsule manufacturing services
      • Oral liquid manufacturing services
      • Semi-solid manufacturing services
      • Other formulations manufacturing services
  • Drug Development Services
  • Biologics Manufacturing Services
    • Biologics API manufacturing services
    • Biologics FDF manufacturing services

Pharmaceutical Contract Development and Manufacturing Market, by End User

  • Big Pharmaceutical Companies
  • Small & Medium-Sized Pharmaceutical Companies
  • Generic Pharmaceutical Companies
  • Other End Users
Europe was the largest regional market for pharmaceutical contract development and manufacturing in 2020.

Geographically, the pharmaceutical contract development and manufacturing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2019, Europe accounted for the largest share of the pharmaceutical contract development and manufacturing market, followed by North America and the Asia Pacific. The large share of this regional segment in the global market can primarily be attributed to the large number of clinical trials in the region, huge API production base, advanced manufacturing capabilities, presence of leading pharmaceutical companies, and growth in the generics market.

Why Buy this Report?

The purpose of Nova one advisor’s Pharmaceutical Contract Development And Manufacturing market study is to provide stakeholders with a detailed picture of potential barriers and untapped opportunities. The report contains exclusive information to assist businesses in making informed decisions about how to maintain growth throughout the assessment period.

Download This Full Research Report, Click Here@

About Us

Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333



James Root

James Root have over 6+ years of experience working in business development, and customer retention. I’ve gained my experience through serving higher education, healthcare, automotive, aerospace, manufacturing, local government and hospitality businesses with technical solutions.

View all posts by James Root →

Leave a Reply

Your email address will not be published.